Document:

Exhibit
10.36

 

SECOND
AMENDMENT TO SECURED CREDIT AGREEMENT

 

SECOND
AMENDMENT TO SECURED CREDIT AGREEMENT dated as of October 27, 2021 (this “Amendment”), between AiPharma
Global Holdings LLC, a Delaware limited liability company (“DE Topco”), AIPHARMA HOLDINGS LIMITED, a company
formed under the laws of the British Virgin Islands (“BVI Holdco”) and AIPHARMA ASIA LIMITED, a company formed under
the laws of Hong Kong (“HK Opco” and together with DE Topco and BVI Holdco, individually and collectively, the “Borrower”)
and Aditxt, Inc., a Delaware corporation (the “Lender”).

 

RECITALS

 

A.
Lender made a loan to Borrower pursuant to a Secured Credit Agreement, dated as of August 27, 2021 (as the same may be amended, supplemented
or otherwise modified from time to time, the “Credit Agreement”).

 

B. Lender
and Borrower desire to amend the Credit Agreement on the terms set forth herein.

 

In
consideration of the mutual covenants and agreements herein contained, the parties hereto agree as follows:

 

		1.	Defined
                                            Terms. Any and all initially capitalized terms used in this Amendment (including, without
                                            limitation, in the Recitals to this Amendment) without definition shall have the respective
                                            meanings assigned thereto in the Credit Agreement.

 

		2.	Additional
                                            Borrowings. Section 2.01(b) of the Credit Agreement is hereby amended and supplemented
                                            add a new clause (v) as follows:

 

(v) Funding
to Third Party. Subject to Lender’s compliance with its internal wire verification process (which may include “know your
customer”, anti-money laundering protocols, and other legal compliance protocols), Lender may, but shall not be required to, fund
Additional Borrowings directly to third-parties, if so requested by Borrower.

 

		3.	Borrowing
                                            Request. Exhibit A to the Credit Agreement is hereby amended and restated in the
                                            form of Exhibit A hereto.

 

		4.	Miscellaneous
                                            Provisions. The provisions of Article VIII of the Credit Agreement are incorporated herein
                                            by this reference mutatis mutandis.

 

[Signature
page follows]

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized officers as of the
day and year first above written.

 

	 	AIPHARMA
    GLOBAL HOLDINGS LLC, a Delaware limited liability company
	 	 
	 	By: 	/s/ Alessandro Gadotti
	 	Name: 	Alessandro Gadotti
	 	Title: 	Legal Representative / CEO
	 	 
	 	AIPHARMA
    HOLDINGS LIMITED, a company formed under the laws of the British Virgin Islands
	 	 
	 	By: 	/s/ Alessandro Gadotti
	 	Name: 	Alessandro Gadotti
	 	Title: 	Legal Representative / CEO
	 	 
	 	AIPHARMA
    ASIA LIMITED, a company formed under the laws of Hong Kong
	 	 
	 	By: 	/s Alessandro Gadotti
	 	Name: 	Alessandro Gadotti
	 	Title: 	Legal Representative / CEO
	 	 
	 	ADITXT,
    INC., a Delaware corporation
	 	 
	 	By:	/s/
Amro Albanna
	 	Name: 	Amro Albanna
	 	Title:	 CEO

 

     

     

    

 

[Exhibit
A]

 

BORROWING
REQUEST

 

To:
Thomas J. Farley, via email at XXXXXXXXXXX

cc: Thomas Eaton via email at XXXXXXXXXXXXX

cc: XXXXXXXXXXXXX

 

Reference
is made to the Secured Credit Agreement, dated as of August 27, 2021 (as amended, restated, or otherwise modified from time to time,
the “Credit Agreement”), by and between AIPHARMA GLOBAL HOLDINGS INC., a Delaware corporation, AIPHARMA HOLDINGS LIMITED,
a company formed under the laws of the British Virgin Islands and AIPHARMA ASIA LIMITED, a company formed under the laws of Hong Kong
(individually and collectively, “Borrower”) and ADITXT, INC., a Delaware corporation (“Lender”)
Capitalized terms used but not defined herein have the respective meanings set forth in the Credit Agreement.

 

		1.	Borrower
                                            hereby requests an Additional Borrowing in the amount of $____________________ pursuant to
                                            the following wire transfer instructions:

 

Beneficiary
name: XXXXXXXXXXXXXXXXX

Address: XXXXXXXXXXXXXXXXXXXXXX

Account Number: XXXXXXXXXXXXX

Routing Number: XXXXXXXXXXXXX

Bank name: XXXXXXXXXXXXXXXX

Bank Address: XXXXXXXXXXXXXXX

Bank Swiftcode: XXXXXXXXXXXXXX

Bank Phone No.: XXXXXXXXXXXXXX

 

		2.	Borrower
                                            hereby requests an Additional Borrowing in the amount of $____________________ to be funded
                                            to _____________________ pursuant to the following wire transfer instructions, and acknowledges
                                            that such Additional Borrower may instead be funded to Borrower’s wire instructions
                                            above. Borrower hereby acknowledges that, each of the delivery of this Borrowing Request
                                            and the acceptance by Borrower of the proceeds of the Additional Borrowing requested hereby
                                            constitute a representation and warranty by the Borrower that, on the date of such additional
                                            Borrowing, both immediately before and after giving effect to the proceeds therefrom, the
                                            statements contained in Article III of the Credit Agreement are true and correct in all material
                                            respects. Borrower further acknowledges that Lender may condition payment to any third party
                                            directed by Borrower upon receipt by Lender of certain representations, warranties and acknowledgements
                                            by such third party with respect to such payments and that Lender in its sole and absolute
                                            discretion may reject the funding under this funding request to a third party:

 

Beneficiary
name:

Address:

Account Number:

Routing Number:

Bank name:

Bank Address:

Bank Swiftcode:

Bank Phone No.:

 

		3.	The
                                            undersigned certifies, on behalf of Borrower and not in his or her individual capacity, that
                                            the Interim Period has not expired pursuant to the terms of the Combination LOI.

 

[Signature
Follows]

 

     

     

    

 

IN
WITNESS WHEREOF, this Closing Certificate is executed by the undersigned as of ___________________________, 2021.

 

	 	

	 	 
	 	Alessandro
    Gadotti, authorized representative of BorrowerExhibit 10.42

 

WARRANT REDUCTION AND RELEASE AGREEMENT

 

WARRANT REDUCTION AND RELEASE
AGREEMENT (the “Agreement”) is made as of November 24, 2021 (the “Effective Date”),
by and between Aditxt, Inc., a Delaware corporation (the “Company”), and the investor signatory hereto (the
“Investor”) (the Company and each Investor are sometimes hereinafter referred to individually as a “Party”
and collectively as the “Parties”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to such
terms in the SPA (as defined below).

 

WHEREAS, the Investor
is the holder of common stock purchase warrants (“Warrants”) issued pursuant to the Securities Purchase Agreement,
dated as of August 25, 2021 (“SPA”);

 

WHEREAS, the Warrants
were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and
Rule 506 promulgated thereunder;

 

WHEREAS, subject to
the terms and conditions set forth in the Agreement, the Company and the Investor wish to reduce the exercise price of the Warrants; and

 

NOW, THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in consideration of the premises and
the mutual agreements, representations and warranties, provisions and covenants contained herein, the parties hereto, intending to be
legally bound hereby, agree as follows:

 

1.1  Reduction
of Exercise Price; Amendment. On the Effective Date, subject to the terms and conditions of this Agreement, the Exercise Price of
the Warrants shall be permanently reduced to equal $1.50, effective immediately without any further action required by either party. Additionally,
the SPA is hereby amended to insert the following in reserved Section 4.11:

 

“4.11 Participation
in Future Financing. 

 

(a)  From
the date hereof until such date that the Company consummates an issuance (or series of issuances, each of which shall be no less than
$5 million) by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents for cash consideration, Indebtedness
or a combination of units thereof (a “Subsequent Financing”) with gross proceeds of at least, in the aggregate, $15
million,, each Purchaser shall have the right to participate, , in an amount equal to their pro-rata portion of 30% of the Subsequent
Financing, on the same terms, conditions and price provided for in the Subsequent Financing; provided, however, that the aggregate maximum
participation amount for all Purchasers shall not exceed $5 million (the “Participation Maximum”) on the same terms,
conditions and price provided for in the Subsequent Financing. 

 

(b)  Between
the time period of 4:00 pm (New York City time) and 6:00 pm (New York City time) on the Trading Day immediately prior to the Trading Day
of the expected announcement of the Subsequent Financing (or, if the Trading Day of the expected announcement of the Subsequent Financing
is the first Trading Day following a holiday or a weekend (including a holiday weekend), between the time period of 4:00 pm (New York
City time) on the Trading Day immediately prior to such holiday or weekend and 2:00 pm (New York City time) on the day immediately prior
to the Trading Day of the expected announcement of the Subsequent Financing), the Company shall deliver to each Purchaser a written notice
of the Company’s intention to effect a Subsequent Financing (a “Subsequent Financing Notice”), which notice shall
describe in reasonable detail the proposed terms of such Subsequent Financing, the amount of proceeds intended to be raised thereunder
and the Person or Persons through or with whom such Subsequent Financing is proposed to be effected and shall include a term sheet and
transaction documents relating thereto as an attachment.

 

     

     

    

 

(c)  Any
Purchaser desiring to participate in such Subsequent Financing must provide written notice to the Company by 6:30 am (New York City time)
on the Trading Day following the date on which the Subsequent Financing Notice is delivered to such Purchaser (the “Notice Termination
Time”) that such Purchaser is willing to participate in the Subsequent Financing, the amount of such Purchaser’s participation,
and representing and warranting that such Purchaser has such funds ready, willing, and available for investment on the terms set forth
in the Subsequent Financing Notice. If the Company receives no such notice from a Purchaser as of such Notice Termination Time, such Purchaser
shall be deemed to have notified the Company that it does not elect to participate in such Subsequent Financing.

 

(d)  If,
by the Notice Termination Time, notifications by the Purchasers of their willingness to participate in the Subsequent Financing (or to
cause their designees to participate) is, in the aggregate, less than the total amount of the Subsequent Financing, then the Company may
effect the remaining portion of such Subsequent Financing on the terms and with the Persons set forth in the Subsequent Financing Notice.

 

(e)  If,
by the Notice Termination Time, the Company receives responses to a Subsequent Financing Notice from Purchasers seeking to purchase more
than the aggregate amount of the Participation Maximum, each such Purchaser shall have the right to purchase its Pro Rata Portion (as
defined below) of the Participation Maximum.”Pro Rata Portion” means the ratio of (x) the Subscription Amount
of Securities purchased on the Closing Date by a Purchaser participating under this Section 4.11 and (y) the sum of the aggregate Subscription
Amounts of Securities purchased on the Closing Date by all Purchasers participating under this Section 4.11.

 

(f)  The
Company must provide the Purchasers with a second Subsequent Financing Notice, and the Purchasers will again have the right of participation
set forth above in this Section 4.11, if the definitive agreement related to the initial Subsequent Financing Notice is not entered into
for any reason on the terms set forth in such Subsequent Financing Notice within two (2) Trading Days after the date of delivery of the
initial Subsequent Financing Notice.

 

(g)  The
Company and each Purchaser agree that, if any Purchaser elects to participate in the Subsequent Financing, the transaction documents related
to the Subsequent Financing shall not include any term or provision that, directly or indirectly, will, or is intended to, exclude one
or more of the Purchasers from participating in a Subsequent Financing, including, but not limited to, provisions whereby such Purchaser
shall be required to agree to any restrictions on trading as to any securities of the Company or be required to consent to any amendment
to or termination of, or grant any waiver, release or the like under or in connection with, this Agreement, without the prior written
consent of such Purchaser. In addition, the Company and each Purchaser agree that, in connection with a Subsequent Financing, the transaction
documents related to the Subsequent Financing shall include a requirement for the Company to issue a widely disseminated press release
by 9:30 am (New York City time) on the Trading Day of execution of the transaction documents in such Subsequent Financing (or, if the
date of execution is not a Trading Day, on the immediately following Trading Day) that discloses the material terms of the transactions
contemplated by the transaction documents in such Subsequent Financing.

 

    2

     

    

 

(h)  Notwithstanding
anything to the contrary in this Section 4.11 and unless otherwise agreed to by such Purchaser, the Company shall either confirm in writing
to such Purchaser that the transaction with respect to the Subsequent Financing has been abandoned or shall publicly disclose its intention
to issue the securities in the Subsequent Financing, in either case in such a manner such that such Purchaser will not be in possession
of any material, non-public information, by 9:30 am (New York City time) on the second (2nd) Trading Day following date of delivery of
the Subsequent Financing Notice. If by 9:30 am (New York City time) on such second (2nd) Trading Day, no public disclosure regarding a
transaction with respect to the Subsequent Financing has been made, and no notice regarding the abandonment of such transaction has been
received by such Purchaser, such transaction shall be deemed to have been abandoned and such Purchaser shall not be deemed to be in possession
of any material, non-public information with respect to the Company or any of its Subsidiaries.

 

(i)  Notwithstanding
the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance.”

 

2.  Closing
Conditions.

 

2.1  Conditions
to Investor’s Obligations. The obligation of the Investor to consummate the transactions contemplated hereby is subject to the
fulfillment, to the Investor’s reasonable satisfaction, prior to or at the Effective Date, of each of the following conditions:

 

(a)  Representations
and Warranties. The representations and warranties of the Company contained in this Agreement shall be true and correct in all material
respects on the date hereof and on and as of the Closing Date as if made on and as of such date.

 

(b)  No
Actions. No action, proceeding, investigation, regulation or legislation shall have been instituted, threatened or proposed before
any court, governmental agency or authority or legislative body to enjoin, restrain, prohibit or obtain substantial damages in respect
of, this Agreement or the consummation of the transactions contemplated by this Agreement.

 

(c)  Proceedings
and Documents. All proceedings in connection with the transactions contemplated hereby and all documents and instruments incident
to such transactions shall be satisfactory in substance and form to the Investor, and the Investor shall have received all such counterpart
originals or certified or other copies of such documents as they may reasonably request.

 

    3

     

    

 

2.2  Conditions
to the Company’s Obligations. The obligation of the Company to consummate the transactions contemplated hereby is subject to
the fulfillment, to the Company’s reasonable satisfaction, prior to or at the Effective Date, of each of the following conditions:

 

(d)  Representations
and Warranties. The representations and warranties of the Investor contained in this Agreement shall be true and correct in all material
respects on the date hereof and on and as of the Effective Date as if made on and as of such date.

 

(e)  No
Actions. No action, proceeding, investigation, regulation or legislation shall have been instituted, threatened or proposed before
any court, governmental agency or authority or legislative body to enjoin, restrain, prohibit, or obtain substantial damages in respect
of, this Agreement or the consummation of the transactions contemplated by this Agreement.

 

(f)  Proceedings
and Documents. All proceedings in connection with the transactions contemplated hereby and all documents and instruments incident
to such transactions shall be satisfactory in substance and form to the Company and the Company shall have received all such counterpart
originals or certified or other copies of such documents as the Company may reasonably request.

 

3.  Representations
and Warranties of the Company. The Company hereby represents and warrants to Investor that:

 

3.1  Organization,
Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the
failure to so qualify would have a material adverse effect on its business or properties.

 

3.2  Authorization.
All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution and
delivery of this Agreement and the performance of all obligations of the Company hereunder, and the reduction to the Exercise Price of
the Warrants, have been taken on or prior to the date hereof.

 

3.3  Compliance
With Laws. The Company has not violated any law or any governmental regulation or requirement which violation has had or would reasonably
be expected to have a material adverse effect on its business and the Company has not received written notice of any such violation.

 

    4

     

    

 

3.4  Validity;
Enforcement; No Conflicts. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Company and
shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in accordance with the terms
hereof, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights
and remedies. The execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the transactions
contemplated hereby will not (i) result in a violation of the organizational documents of the Company or (ii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company is a party or by which it is bound,
or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities or “blue
sky” laws) applicable to the Company, except in the case of clause (ii) above, for such conflicts, defaults or rights which would
not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Company to perform
its obligations hereunder.

 

3.5  Disclosure.
The Company confirms that neither it nor any other person acting on its behalf has provided the Investor or its agents or counsel with
any information that constitutes or could reasonably be expected to constitute material, nonpublic information. The Company understands
and confirms that the Investor will rely on the foregoing representations in effecting the amendment to the Warrants.

 

4.  Representations
and Warranties of the Investor. The Investor hereby represents, warrants and covenants that:

 

4.1  Authorization.
The Investor has full power and authority to enter into this Agreement, to perform its obligations hereunder and to consummate the transactions
contemplated hereby and has taken all action necessary to authorize the execution and delivery of this Agreement, the performance of its
obligations hereunder and the consummation of the transactions contemplated hereby.

 

4.2  Investment
Experience. The Investor can bear the economic risk of its investment in the Securities, and has such knowledge and experience in
financial and business matters that it is capable of evaluating the merits and risks of an investment in the Company.

 

4.3  Information.
The Investor and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of the
Company and materials relating to the amendment of the Warrants which have been requested by the Investor. The Investor has had the opportunity
to review the Company’s filings with the Commission. The Investor and its advisors, if any, have been afforded the opportunity to ask
questions of the Company. Neither such inquiries nor any other due diligence investigations conducted by the Investor or its advisors,
if any, or its representatives shall modify, amend or affect the Investor’s right to rely on the Company’s representations
and warranties contained herein. The Investor understands that its investment in the Company involves a high degree of risk. The Investor
has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to
the amendment of the Warrants. The Investor is relying solely on its own accounting, legal and tax advisors, and not on any statements
of the Company or any of its agents or representatives, for such accounting, legal and tax advice with respect to the amendment of the
Warrants and the transactions contemplated by this Agreement.

 

    5

     

    

 

4.4  No
Governmental Review. The Investor understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Warrants or the fairness or suitability of the investment in the
Company nor have such authorities passed upon or endorsed the merits of the offering of the Shares.

 

4.5  Validity;
Enforcement; No Conflicts. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Investor and
shall constitute the legal, valid and binding obligations of the Investor enforceable against the Investor in accordance with the terms
hereof, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights
and remedies. The execution, delivery and performance by the Investor of this Agreement and the consummation by the Investor of the transactions
contemplated hereby will not (i) result in a violation of the organizational documents of the Investor or (ii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Investor is a party, or (iii) result in
a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities or “blue sky”
laws) applicable to the Investor, except in the case of clause (ii) above, for such conflicts, defaults or rights which would not, individually
or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Investor to perform its obligations
hereunder.

 

5.  Additional
Covenants.

 

5.1  Disclosure.
The Company shall, on or before 9:30 a.m., New York City time, on the business day after the date of this Agreement, issue a Current Report
on Form 8-K (the “8-K Filing”) disclosing all material terms of the transactions contemplated hereby. From and
after the issuance of the 8-K Filing, the Investor shall not be in possession of any material, nonpublic information received from the
Company or any of its respective officers, directors, employees or agents that is not disclosed in the 8-K Filing. The Company shall not,
and shall cause its officers, directors, employees and agents, not to, provide the Investor with any material, nonpublic information regarding
the Company from and after the filing of the 8-K Filing without the express written consent of the Investor. The Company shall not disclose
the name of the Investor in any filing, announcement, release or otherwise, unless such disclosure is required by law or regulation. In
addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similar
obligations under any agreement, whether written or oral, between the Company, any of its subsidiaries or any of their respective officers,
directors, affiliates, employees or agents, on the one hand, and the Investor or any of its affiliates, on the other hand, shall terminate.

 

    6

     

    

 

5.2  Release
and Covenant Not to Sue.

 

5.2.1  On
the Effective Date, each Party, on its own behalf and on behalf of its affiliates, investors, members and equity holders (each, a “Releasing
Party” and, collectively, the “Releasing Parties”), does hereby completely, unconditionally and
irrevocably release the other Party and the other Party’s current and former officers, directors, employees attorneys, accountants,
agents, financial advisors and other representatives, and each of its respective heirs, successors and permitted assigns (each, a “Releasee”
and, together, the “Releasees”) from and with respect to any and all claims, obligations, suits, judgments,
damages, rights, causes of action, demands, debts and liabilities whatsoever, whether known or unknown, foreseen or unforeseen, existing
or hereafter arising, in law, equity or otherwise (collectively, the “Claims”), that such Releasing Parties
are entitled to assert against any of the Releasees, based solely on the Company’s representations and warranties under Sections
3.1(d) or 3.1(g) of the SPA regarding the facts and circumstances relating to the Defeasance and Waiver Agreement, dated as of August
30, 2021, by and between the Company and the party named therein, at the time the Investor made its investment decision with respect to
the transactions contemplated under the SPA.

 

5.2.2  It
is a further condition of the consideration hereof and is the intention of each Releasing Party in executing this instrument that the
same shall be effective as a bar as to each and every claim, demand and cause of action hereinabove specified and, in furtherance of this
intention, such Releasing Party hereby expressly waives any and all rights or benefits conferred by any provision of law that prevents
the release of unknown claims and expressly consents that this Agreement shall be given full force and effect according to each and all
of its express terms and conditions including, without limitation, those relating to unknown and unsuspected claims, demands and causes
of actions, if any, as well as those relating to any other claims, demands and causes of actions hereinabove specified.

 

5.2.3  Each
of the Releasing Parties hereby absolutely, unconditionally and irrevocably covenants and agrees with and in favor of each of the Releasees
that it will not sue or bring any action or proceeding (at law, in equity, in any regulatory, mediation or arbitration proceeding or otherwise)
against any Releasee on the basis of any of the Claims released hereby.

 

5.2.4  Each
of the Releasing Parties hereby agrees that this Agreement and the covenant not to sue set forth herein may be pleaded as a full and complete
defense and may be used as a basis for an injunction against any action, suit or other proceeding that may be instituted, prosecuted or
attempted in breach of the provisions of this Agreement. Each of the Releasing Parties hereby agrees that no fact, event, circumstance,
evidence or transaction that could now be asserted or that may hereafter be discovered shall affect in any manner the final, absolute
and unconditional nature of this Agreement and the covenant not to sue set forth herein.

 

    7

     

    

 

5.2.5  It
is hereby understood and agreed that the acceptance of this Agreement by either Party shall not be deemed or construed as an admission
of liability of any nature whatsoever arising from or related to the subject of this Agreement.

 

5.2.6  Except
as required by applicable law or the rules or regulations of any governmental authority or by the order of any court of competent jurisdiction,
each Party agrees that such Party shall not, directly or indirectly (through such Party’s related parties or otherwise), make, publish
or cause to be made or published any statement or remark concerning the subject matter of the SPA, this Agreement, the participation or
involvement of the Parties in the transactions contemplated by the SPA or the reasons for or any of the events or circumstances surrounding
the transactions contemplated by this Agreement that could reasonably be understood as disparaging the business or conduct of the other
Parties or their respective related parties or as intended to harm the business or reputation of the other Parties or their respective
related parties.

 

5.3  Fees
and Expenses. Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all
other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement.

 

6.  Miscellaneous.

 

6.1  Successors
and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be
binding upon the parties hereto and the respective successors and assigns of the parties. Nothing in this Agreement, express or implied,
is intended to confer upon any party, other than the parties hereto or their respective successors and assigns, any rights, remedies,
obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

6.2  Governing
Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision
or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions
other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state or federal courts sitting
in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any
claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient
forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process
and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for
such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH
PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER
OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

    8

     

    

 

6.3  Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing
or interpreting this Agreement.

 

6.4  Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in
writing and will be deemed to have been delivered pursuant to the terms of the SPA.

 

6.5  Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally
or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Investor.
Any amendment or waiver effected in accordance with this paragraph shall be binding upon Investor and the Company, provided that no such
amendment shall be binding on a holder that does not consent thereto to the extent such amendment treats such party differently than any
party that does consent thereto.

 

6.6  Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this
Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance
with its terms.

 

6.7  Entire
Agreement. This Agreement represents the entire agreement and understanding between the parties concerning the amendment to the Warrants
and the other matters described herein and therein and supersede and replaces any and all prior agreements and understandings solely with
respect to the subject matter hereof and thereof.

 

6.8  Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

 

6.9  Interpretation.
Unless the context of this Agreement clearly requires otherwise, (a) references to the plural include the singular, the singular the plural,
the part the whole, (b) references to any gender include all genders, (c) “including” has the inclusive meaning frequently
identified with the phrase “but not limited to” and (d) references to “hereunder” or “herein” relate
to this Agreement.

 

6.10  No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

6.11  Survival.
The representations, warranties and covenants of the Company and the Investor contained herein shall survive the Closing and delivery
of the Shares.

 

6.12  Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

6.13  No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their
mutual intent, and no rules of strict construction will be applied against any party.

 

[SIGNATURES ON
THE FOLLOWING PAGES]

 

    9

     

    

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be duly executed and delivered as of the date provided above.

 

	 	THE COMPANY
	 	 	 
	 	ADITXT, INC.
	 	 	 
	 	By:	 
	 	Name:	Amro Albanna
	 	Title:	Chief Executive Officer
	 	 	 

 

    10

     

    

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be duly executed and delivered as of the date provided above.

 

INVESTOR

 

Name of Investor: ________________________________________________________

 

Signature of Authorized Signatory of Investor:
__________________________________

 

Name of Authorized Signatory: ____________________________________________________

 

Title of Authorized Signatory: _____________________________________________________

 

Email Address of Authorized Signatory: _____________________________________________

 

 

11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]